ArticleOphthalmology2012
Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management.
Article in Ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.The British journal of ophthalmology · 2017Pooled it
- Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis.BMC ophthalmology · 2017Pooled it
- VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).JAMA ophthalmology · 2014Trial
- Article
- Integrating explainable machine learning and transcriptomics data reveals cell-type specific immune signatures underlying macular degeneration.NPJ genomic medicine · 2025Article
- Single-cell transcriptome atlas of spontaneous dry age-related macular degeneration in macaques.Fundamental research · 2025Article
- Gene therapy for geographic atrophy in age-related macular degeneration: current insights.Eye (London, England) · 2025Review
- Association of serum 25-hydroxyvitamin D levels with age-related macular degeneration and its clinical correlates: a cross-sectional study.Frontiers in endocrinology · 2025Observational
- The Complement Factor H (Y402H) risk polymorphism for age-related macular degeneration affects metabolism and response to oxidative stress in the retinal pigment epithelium.Free radical biology & medicine · 2024Article
- Single-Cell Multiomics Profiling Reveals Heterogeneity of Müller Cells in the Oxygen-Induced Retinopathy Model.Investigative ophthalmology & visual science · 2024Article
- Genetic Insights into Age-Related Macular Degeneration.Biomedicines · 2024Review
- Treating patients with geographic atrophy: are we there yet?International journal of retina and vitreous · 2023Review
- CFH Loss in Human RPE Cells Leads to Inflammation and Complement System Dysregulation via the NF-κB Pathway.International journal of molecular sciences · 2021Article
- A Systematic Review of Carotenoids in the Management of Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2021Review
- The complement system in age-related macular degeneration.Cellular and molecular life sciences : CMLS · 2021Review
- Family-based exome sequencing identifies rare coding variants in age-related macular degeneration.Human molecular genetics · 2020Article
- Rare Genetic Variants in Jewish Patients Suffering from Age-Related Macular Degeneration.Genes · 2019Article
- Vitamin D Attenuates Oxidative Damage and Inflammation in Retinal Pigment Epithelial Cells.Antioxidants (Basel, Switzerland) · 2019Article
- Models of retinal diseases and their applicability in drug discovery.Expert opinion on drug discovery · 2018Review
- Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders.International journal of ophthalmology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAge-related macular degeneration (AMD) is a common cause of visual impairment in individuals >55 years of age worldwide. The varying clinical phenotypes of AMD result from contributions of genetic, epigenetic, and nongenetic (environmental) factors. Genetic studies of AMD have come of age as a direct result of tremendous gains from the human genome project, genome-wide association studies, and identification of numerous susceptibility loci. These findings have implicated immune response, high-density lipoprotein cholesterol metabolism, extracellular matrix, and angiogenesis signaling pathways in disease pathophysiology.
main outcome measuresHerein, we address how the wealth of genetic findings in AMD is expected to impact the practice of medicine, providing opportunities for improved risk assessment, molecular diagnosis, preventive, and therapeutic intervention.
conclusionsWe propose that the potential of using genetic variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized medicine in the clinical management of AMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.